People in the study are placed into one of two groups. One group has the blood flow checked with indocyanine green fluorescence imaging, which means the dye is used so the surgeon can see how blood moves through the flap. The other group is checked with standard clinical assessment, which means the usual way of judging the flap during surgery. After the operation, the flap is followed for a short time to see how it heals and whether any further treatment is needed.

The study is for people whose cancer has gotten worse after treatment with platinum-based chemotherapy and anti-PD-L1 or anti-PD-1 therapy, which are treatments that help the immune system fight cancer. Treatment of physician’s choice may include topotecan, tisotumab vedotin, irinotecan, pemetrexed, gemcitabine, or vinorelbine, and some medicines may be given with supportive care such as paracetamol, H2-receptor antagonists, and glucocorticoids to help reduce side effects. The study is randomized, which means treatment is assigned by chance, and it is open-label, which means both the study team and the participant know which treatment is being given.

The study has an initial part and then a larger comparison part. In the first part, MK-2870 is given to gather early information about how it acts in the body and how well it is tolerated. In the main part, MK-2870 is compared with other available cancer treatments. Treatment is given over time, with regular study visits and checks for side effects and general health while the cancer is being followed.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The main aim is to see if the drug is safe and can shrink or stop the growth of these cancers. Children will receive the medicine in a series of visits where doctors check for side effects, adjust the dose if needed, and use simple scans to see whether the tumor is getting smaller. The study follows participants for several months to record any problems and to determine whether the cancer responds, using terms like “objective response rate” (the percentage of children whose tumors shrink) and “disease control” (tumors that stay the same size or get smaller).

The purpose of the study is to assess how satisfied patients are with using Zeqmelit™ compared to their usual treatment, especially during an acute allergic reaction. Participants in the study will use the mouth-dissolving film and provide feedback on their overall satisfaction, including how safe they feel using it. The study will also gather information on the participants’ experiences with the treatment, such as their choice of treatment and access to it, as well as their perception of its effectiveness.

Throughout the study, participants will be asked to answer questions about their satisfaction and experiences with the treatment. This will help researchers understand how Zeqmelit™ compares to standard treatments for acute allergic reactions. The study is designed to be low-intervention, meaning it aims to minimize any disruption to the participants’ usual treatment routines.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The study is designed as a split-body study, which means that different treatments will be applied to different areas of the body on the same person. Before starting the maintenance treatment with the creams, patients will first receive treatment with a corticosteroid cream, which is a medication that reduces inflammation, for about four weeks to clear the skin lesions. Corticosteroids are commonly used to treat skin inflammation and help calm down active eczema flare-ups. Once the skin has cleared, the maintenance phase begins, where one moisturizing cream will be applied to one study area on the body, another cream or no treatment will be applied to another area, and this will continue for up to 90 days or until the eczema comes back.

During the study, the time it takes for the eczema to return on each treated area will be measured, which is the main focus of the research. Other aspects that will be looked at include how itching changes over time in the different areas and whether any unwanted effects occur during the treatment period. Patients will report when they notice their eczema returning and how much itching they experience using a rating scale.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this research is to evaluate how well different doses of Rocatinlimab work compared to placebo in reducing itching in people with Prurigo Nodularis. The medication will be given as a subcutaneous injection (an injection under the skin). The study will last for 52 weeks, during which participants will receive either Rocatinlimab or placebo.

Throughout the study, participants will need to keep a daily record of their symptoms, including itching intensity and skin pain. Doctors will regularly examine the skin nodules and monitor how the treatment affects participants’ quality of life and sleep. The study will also track any side effects that may occur during the treatment period.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to determine whether the drug can improve kidney function compared with placebo. Kidney function will be assessed by measuring how well the kidneys filter waste, using a test called creatinine clearance, during the first few hours after the infusion starts.

After the surgery, eligible infants are randomly assigned to receive the study medication or placebo. The infusion is given over a short period, and blood and urine samples are collected for safety checks and to evaluate kidney performance. The children are then observed for about two days to monitor urine output, fluid balance, and any signs of kidney problems, with follow‑up continuing until the study ends.

The purpose of this study is to find out whether the study medications are better than placebo at reducing the occurrence of major liver-related complications. During the study, researchers will monitor participants for various liver problems including progression to cirrhosis (severe liver scarring), development of complications like varices (enlarged veins in the digestive tract), ascites (fluid buildup in the abdomen), hepatic encephalopathy (brain function problems caused by liver disease), and other serious liver conditions. The study will also track whether participants need liver transplantation or experience other serious outcomes.

Participants in this study will receive their assigned treatment over an extended period while being regularly monitored by the study team. The study requires participants to have evidence of liver fat confirmed by MRI (a type of imaging scan) and liver scarring confirmed through non-invasive tests, though a liver biopsy is not required to join the study. Throughout the study, participants will have regular check-ups and assessments to evaluate how well the treatment is working and to monitor their liver health and overall wellbeing.